Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

A. Bjartell, L. Costa, G. Kramer, B. Zurawski, L. Galli, P. Werbrouck, T. Ecke, O. Parikh, M. Bennamoun, C. Garcia Freire, A. Peer, B. Ljungberg, I. Cicin, E. Smith, M. Lukac, R. Wapenaar, S. Chowdhury

. 2022 ; 45 (-) : 12-22. [pub] 20220917

Status neindexováno Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031390

BACKGROUND: Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC. DESIGN SETTING AND PARTICIPANTS: A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted. INTERVENTION: Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone-radium-223 (ABI-RAD), docetaxel-abiraterone (DOCE-ABI), docetaxel-cabazitaxel (DOCE-CABA), docetaxel-enzalutamide (DOCE-ENZA), and enzalutamide-docetaxel (ENZA-DOCE). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline patient characteristics, quality of life, mCRPC treatments, and efficacy outcomes (progression and survival) were presented descriptively. RESULTS AND LIMITATIONS: Data from 727 patients were eligible for the analysis (ABI-DOCE n = 178, ABI-ENZA n = 99, ABI-RAD n = 27, DOCE-ABI n = 191, DOCE-CABA n = 74, DOCE-ENZA n = 116, and ENZA-DOCE n = 42). Demographics and disease characteristics among patients between different sequences varied greatly. Most patients who started on abiraterone or enzalutamide stopped therapy because of disease progression. No randomisation to allow treatment/sequence comparisons limited this observational study. CONCLUSIONS: The real-world PCR data complement clinical trial data, reflecting more highly selected patient populations than seen in routine clinical practice. Baseline characteristics play a role in mCRPC first-line treatment selection, but other factors, such as treatment availability, have an impact. Efficacy observations are limited and should be interpreted with caution. PATIENT SUMMARY: Baseline characteristics appear to have a role in the first-line treatment selection of metastatic castration-resistant prostate cancer in the real-world setting. First-line abiraterone acetate plus prednisone seems to be the preferred treatment option for older patients and those with lower Gleason scores, first-line docetaxel for younger patients and those with more advanced disease, and first-line enzalutamide for patients with fewer metastases and more favourable performance status. The benefit to patients from these observations remains unknown.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031390
003      
CZ-PrNML
005      
20230127131143.0
007      
ta
008      
230119s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euros.2022.08.018 $2 doi
035    __
$a (PubMed)36353661
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bjartell, Anders $u Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
245    10
$a Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry / $c A. Bjartell, L. Costa, G. Kramer, B. Zurawski, L. Galli, P. Werbrouck, T. Ecke, O. Parikh, M. Bennamoun, C. Garcia Freire, A. Peer, B. Ljungberg, I. Cicin, E. Smith, M. Lukac, R. Wapenaar, S. Chowdhury
520    9_
$a BACKGROUND: Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC. DESIGN SETTING AND PARTICIPANTS: A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted. INTERVENTION: Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone-radium-223 (ABI-RAD), docetaxel-abiraterone (DOCE-ABI), docetaxel-cabazitaxel (DOCE-CABA), docetaxel-enzalutamide (DOCE-ENZA), and enzalutamide-docetaxel (ENZA-DOCE). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Baseline patient characteristics, quality of life, mCRPC treatments, and efficacy outcomes (progression and survival) were presented descriptively. RESULTS AND LIMITATIONS: Data from 727 patients were eligible for the analysis (ABI-DOCE n = 178, ABI-ENZA n = 99, ABI-RAD n = 27, DOCE-ABI n = 191, DOCE-CABA n = 74, DOCE-ENZA n = 116, and ENZA-DOCE n = 42). Demographics and disease characteristics among patients between different sequences varied greatly. Most patients who started on abiraterone or enzalutamide stopped therapy because of disease progression. No randomisation to allow treatment/sequence comparisons limited this observational study. CONCLUSIONS: The real-world PCR data complement clinical trial data, reflecting more highly selected patient populations than seen in routine clinical practice. Baseline characteristics play a role in mCRPC first-line treatment selection, but other factors, such as treatment availability, have an impact. Efficacy observations are limited and should be interpreted with caution. PATIENT SUMMARY: Baseline characteristics appear to have a role in the first-line treatment selection of metastatic castration-resistant prostate cancer in the real-world setting. First-line abiraterone acetate plus prednisone seems to be the preferred treatment option for older patients and those with lower Gleason scores, first-line docetaxel for younger patients and those with more advanced disease, and first-line enzalutamide for patients with fewer metastases and more favourable performance status. The benefit to patients from these observations remains unknown.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Costa, Luis $u Oncology Division, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal $u Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal $u Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal
700    1_
$a Kramer, Gero $u Department of Urology, Medical University of Vienna, Vienna, Austria
700    1_
$a Zurawski, Bogdan $u Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Dzial Onkologii Klinicznej, Ambulatorium Chemioterapii, Bydgoszcz, Poland
700    1_
$a Galli, Luca $u Pisana University Hospital, Pisa, Italy
700    1_
$a Werbrouck, Patrick $u AZ Groeninge, Kortrijk, Belgium
700    1_
$a Ecke, Thorsten $u Helios Klinikum Bad Saarow, Bad Saarow, Germany
700    1_
$a Parikh, Omi $u Royal Blackburn Hospital, Blackburn, UK
700    1_
$a Bennamoun, Mostefa $u Institut Mutualiste Montsouris, Paris, France
700    1_
$a Garcia Freire, Camilo $u Hospital Clínico Universitario de Santiago, Servicio de Urología, Santiago de Compostela, Spain
700    1_
$a Peer, Avivit $u Rambam Medical Center, Haifa, Israel
700    1_
$a Ljungberg, Börje $u Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden
700    1_
$a Cicin, Irfan $u Trakya University Hospital Medical Oncology Department, Edirne, Turkey
700    1_
$a Smith, Emma $u Janssen-Cilag, High Wycombe, UK
700    1_
$a Lukac, Martin $u Parexel International Czech Republic sro, on behalf of Janssen Pharmaceutica NV, Beerse, Belgium
700    1_
$a Wapenaar, Robert $u Janssen-Cilag BV, Breda, The Netherlands
700    1_
$a Chowdhury, Simon $u Guy's and St Thomas' NHS Foundation Trust and Sarah Cannon Research Institute, London, UK
773    0_
$w MED00207999 $t European urology open science $x 2666-1683 $g Roč. 45, č. - (2022), s. 12-22
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36353661 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131134 $b ABA008
999    __
$a ok $b bmc $g 1889482 $s 1182723
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 45 $c - $d 12-22 $e 20220917 $i 2666-1683 $m European urology open science $n Eur Urol Open Sci $x MED00207999
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Možnosti archivace